---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-005736"
form_type: "8-K"
ticker: "INBS"
cik: "0001725430"
company_name: "INTELLIGENT BIO SOLUTIONS INC."
filed_at: "2024-02-09T23:59:59+00:00"
generated_at: "2026-06-06T04:54:41.272257+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Intelligent Bio Solutions Q2 revenue up 114% YoY to $0.76M; net loss widens

## Summary
- Revenue from sales of goods increased 114% to $0.76M in Q2 FY2024, and 337% to $1.56M for six months ended Dec 31, 2023.
- Net loss attributable to INBS for six months was $4.39M, compared to $1.63M in prior year, driven by acquisition of IFP.
- Company raised ~$4.38M in October 2023 public offering; net proceeds ~$3.79M; ended quarter with $1.12M cash.
- Expanded into New Zealand market; customer portfolio includes VKVP Haulage, Titan Cranes, P&O Ferries; NATA accreditation for confirmatory drug testing.
- Product sales grew 30% for cartridges and 91% for readers in six months; management expects continued rapid growth in 2024.

## SEC filing metadata
- accession: 0001493152-24-005736
- form_type: 8-K
- ticker: INBS
- cik: 0001725430
- company_name: INTELLIGENT BIO SOLUTIONS INC.
- filed_at: 2024-02-09T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1725430/000149315224005736/0001493152-24-005736-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1725430/000149315224005736/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-005736
- JSON: https://secwatch.observer/filing/0001493152-24-005736.json
- Plain text: https://secwatch.observer/filing/0001493152-24-005736.txt

## Key facts
- Earnings Releases
  INTELLIGENT BIO SOLUTIONS INC. reported financial results for fiscal second quarter and six months ended December 31, 2023.
  - Period: fiscal second quarter and six months ended December 31, 2023
  - Result: reported results
  source text: On February 9, 2024, Intelligent Bio Solutions Inc. (the “Company”), issued a press release (the “Press Release”) announcing financial results for the three months ended December 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1725430/000149315224005736/0001493152-24-005736-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.